Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review DOI Creative Commons
Sara Tedeschi, Efthymia Giannitsioti, Christian Mayer

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(5), P. 963 - 963

Published: April 23, 2025

Due to the involvement of biofilms in pathogenesis bone and joint infections (BJI), treatment these is often challenging, especially when multidrug- or extensively drug-resistant (MDR/XDR) pathogens are involved. Intravenous fosfomycin (FOS) a phosphoenolpyruvate analogue with unique mode action broad-spectrum activity against both Gram-positive (GP) Gram-negative (GN) pathogens. It used various severe deep-seated infections, including BJIs. This review article focuses on preclinical clinical data surrounding use FOS for biofilm-related Data from several vitro animal models infection demonstrated that FOS, combination other antibiotics, effective (methicillin-resistant) Staphylococcus spp., (vancomycin-resistant) Enterococcus carbapenem-resistant extended-spectrum beta-lactamase-producing Enterobacterales, MDR Pseudomonas aeruginosa. studies, mostly retrospective observational studies case reports/case series, revealed was typically antibiotics BJI, acute chronic osteomyelitis, prosthetic fracture-related adult pediatric patients. Success rates exceeded 80%. exhibits good fast penetration into tissue generally well tolerated, only few adverse drug reactions, such as gastrointestinal disorders electrolyte imbalances. Collectively, indicate valuable option part regimens BJIs caused by GP GN bacteria.

Language: Английский

Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review DOI Creative Commons
Sara Tedeschi, Efthymia Giannitsioti, Christian Mayer

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(5), P. 963 - 963

Published: April 23, 2025

Due to the involvement of biofilms in pathogenesis bone and joint infections (BJI), treatment these is often challenging, especially when multidrug- or extensively drug-resistant (MDR/XDR) pathogens are involved. Intravenous fosfomycin (FOS) a phosphoenolpyruvate analogue with unique mode action broad-spectrum activity against both Gram-positive (GP) Gram-negative (GN) pathogens. It used various severe deep-seated infections, including BJIs. This review article focuses on preclinical clinical data surrounding use FOS for biofilm-related Data from several vitro animal models infection demonstrated that FOS, combination other antibiotics, effective (methicillin-resistant) Staphylococcus spp., (vancomycin-resistant) Enterococcus carbapenem-resistant extended-spectrum beta-lactamase-producing Enterobacterales, MDR Pseudomonas aeruginosa. studies, mostly retrospective observational studies case reports/case series, revealed was typically antibiotics BJI, acute chronic osteomyelitis, prosthetic fracture-related adult pediatric patients. Success rates exceeded 80%. exhibits good fast penetration into tissue generally well tolerated, only few adverse drug reactions, such as gastrointestinal disorders electrolyte imbalances. Collectively, indicate valuable option part regimens BJIs caused by GP GN bacteria.

Language: Английский

Citations

0